Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. presents a promising investment opportunity due to its innovative approach to developing allogeneic NK cell therapies, which harness the natural cytotoxicity of NK cells for cancer treatment. The company's decision to reintegrate standardized lymphodepletion with fludarabine has positively impacted patient enrollment, enhancing its clinical trial progress. Furthermore, Nkarta is positioned in an emerging therapeutic category that offers numerous biological and logistical advantages over existing CAR-T therapies, suggesting potential for significant growth and value creation.

Bears say

Nkarta Inc's recent financials reflect a concerning trend, with research and development (R&D) spending down 14% sequentially to $21 million, which raises questions about the company's commitment to advancing its clinical programs. Additionally, the company has reported a substantial reduction in selling, general, and administrative (SG&A) expenses, falling 48% sequentially to $6 million, indicating potential cutbacks in operational capabilities. Furthermore, the decision to postpone preliminary year-end data disclosures in favor of a comprehensive update at a later medical conference may signal uncertainty regarding the efficacy of their ongoing studies, further contributing to a negative outlook on the company's stock.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.